Compare Thomson Reuters Corp (TRI) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Thomson Reuters Corp vs Zoetis Inc — how do they compare? Thomson Reuters Corp trades at $90.98 (market cap $41.28B), while Zoetis Inc trades at $76.07 (market cap $31.95B). The key difference: Thomson Reuters Corp is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| TRI | ZTS | |
|---|---|---|
Market Cap | $41.28B | $31.95B |
Sector | Industrials | Health |
52-Week High | $205.54 | $156.76 |
52-Week Low | $76.55 | $71.91 |
Enterprise Value | $43.24B | $39.24B |
Dividend Yield | 2.75% | 2.78% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
